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Peptidoglycan, the substance in mycobacteria thought to be responsible for inducing adju-
vant arthritis, and endotoxin (lipopolysaccharide or LPS) share many inflammatory proper-
ties. Since repeated administration of LPS produces tolerance, i.e., resistance to the toxic and
inflammatory effects ofLPS, we tested whether LPS and/or LPS tolerance might influence in-
flammation due to mycobacterial adjuvant. Male Sprague-Dawley rats were injected with
Escherichia coli LPS or saline intraperitoneally and then challenged with 100 ytg killed
Mycobacteria butyricum (adjuvant) in the footpad. A single dose of 100 Ag LPS three or 24
hours before adjuvant markedly, but transiently, reduced the local footpad swelling that
begins within hours of the adjuvant injection and histologically resembles a sterile abscess.
Animals that received multiple doses of LPS and were therefore tolerant or animals that re-
ceived LPS 72 hours before adjuvant demonstrated adjuvant-induced footpad swelling nearly
equal to controls. The anti-inflammatory effect of LPS was transient since footpad swelling in
all groups was nearly comparable six days after the adjuvant injection and LPS failed to inhibit
consistently the arthritis that develops two or more weeks after adjuvant injection. These
studies establish that LPS can markedly inhibit the prodrome of adjuvant arthritis (footpad
swelling due to M. butyricum), that inhibition of this prodrome does not prevent the subse-
quent development of arthritis, and that LPS tolerance diminishes this anti-inflammatory ef-
fect of LPS.
INTRODUCTION
Lipopolysaccharide (LPS or endotoxin) induces inflammation in experimental
animals. Direct or indirect inflammatory effects of LPS include fever [1], activation
of the complement [2], coagulation [3], and kinin cascades [4], increased vascular
permeability [5], increased prostaglandin synthesis [6], and activation of polymor-
phonuclear leukocytes [7], lymphocytes [8], monocyte-macrophages [6], and
platelets [9].
Less well appreciated is that LPS may be anti-inflammatory as well. In 1955,
Humphrey [10] noted that polysaccharides from gram-negative bacteria could in-
hibit reversed passive Arthus reactions in rabbit skin but believed that the effect
might be an artefact due to hypotension. Subsequent investigators have dem-
onstrated that endotoxin can inhibit active Arthus reactions in guinea pig and rabbit
[11], and it can reduce the cellular infiltrate that follows the intraperitoneal injection
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of a variety of irritants into mice [12]. Pyrogen, usually in the form of endotoxin,
was believed to be an effective form of therapy for arthritis in man [13]. Ex-
periments in our own laboratory have begun to explore the mechanism of LPS-
induced anti-inflammatory effects [14]. These studies in rabbits indicate that in-
travenous LPS inhibits the chemotactic responsiveness of polymorphonuclear
leukocytes to complement-derived peptides without inhibiting the ability to respond
to another chemoattractant, n-formyl-methionyl-leucyl-phenylalanine [14].
Adjuvant arthritis is a widely employed model for experimental arthritis in rats
[15-20]. In susceptible strains, this arthritis can be readily induced by an injection of
killed mycobacteria in mineral oil (adjuvant) [19]. The arthritogenic component ofthe
mycobacteria is believed to be peptidoglycan (PG), since PG from a variety of
sources other than mycobacteria induces a similar arthritis [18]. PG and LPS share a
number of inflammatory properties. For example, both induce fever [21], activate
complement, activate macrophages [22], act as an adjuvant [23], and cause gelation
oflimulus lysates [24]. Repeated injections of LPS induce a state ofrefractoriness to
both its toxic effects, such as lethargy, fever, and diarrhea [25], and at least some of
its inflammatory effects [5,26,27]. For example, in rabbits a single injection of LPS
induces ocular vascular permeability [5], the generation of chemotactic activity in
the aqueous humor [27], and a rise in aqueous humor prostaglandin E2 [27]. Rabbits
tolerant to endotoxin by virtue of a daily injection for five days show no change in
ocular vascular permeability, no generation of chemotactic activity in the aqueous
humor, and no rise in aqueous humor prostaglandin E2 subsequent to intravenous
LPS [5,27]. Similarly, 100 ,ug of LPS injected intraperitoneally to rats induces eye in-
flammation [26], but multiple injections of LPS inhibit this inflammatory change
[26]. Although known as tolerance, this state should not be confused with im-
munologic tolerance, since tolerance to LPS may result from an immune response
rather than the lack of an immune response [25].
We therefore studied whether LPS and/or LPS tolerance could inhibit inflamma-
tion due to mycobacterial adjuvant. We demonstrate that a single injection of LPS
potently but transiently inhibits the local footpad swelling that develops soon after
the mycobacterial injection. LPS does not consistently affect the systemic arthritis
that develops two weeks after adjuvant injection. Since animals tolerant to LPS
show relative resistance to inflammation induced by LPS, and since PG and LPS
share inflammatory effects, we hypothesized that animals tolerant to LPS would
show a marked reduction in their inflammatory response to PG. Paradoxically, LPS
tolerance diminished the anti-inflammatory effects of a single dose of LPS.
METHODS
Animals
Male Sprague-Dawley rats (160-200 g) were purchased from Simonsen Labora-
tories (Gilroy, CA) and fed standard laboratory chow.
Reagents and Experimental Protocol
Killed Mycobacteria butyricum and Escherichia Coli055:B5 LPS (phenol extract)
were purchased from Difco (Detroit, MI). The M. butyricum was ground with a
mortar and pestle and suspended in a mineral and enema oil mixture. It wasinjected
in a volume of0.1 ml (1 mg mycobacteria/ml) into a hind footpad on the first day of
study(Day0). LPS was suspended inpyrogen-free saline (McGaw Laboratories) and
stored at -20°C until use. It was injected intraperitoneally in a volume of 0.1 ml
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(1 mg/ml) in a variety of schedules, as given in the results. This dose of endotoxin
produced transient lethargy and diarrhea in virtually all animals. It is fatal to ap-
proximately 10 percent of animals. Control animals received intraperitoneal injec-
tions ofsterile, pyrogen-free saline. Footpad diameter as measured with appropriate
calipers was used as an index of arthritis in the uninjected footpad or as a quantita-
tion of soft tissue swelling in the injected footpad [15,17]. Readings were done by an
observer unaware of the treatment the rats had received. Readings taken in this
fashion were reproducible and comparable determinations were obtained ifthe foot-
pad measurements were repeated by a second independent observer.
Complement Determination
Total hemolytic complement titers were measured in rat serum using a microtiter
assay [28]. Sheep erythrocytes were sensitized with heat-inactivated rabbit anti-sheep
hemolysin (Difco) and suspended in gelatin-veronal buffer, pH 7.35, at a concentra-
tion of 5 x 10' cells/ml. Hemolysis was determined after 60 minutes of incubation
ofsensitized sheep erythrocytes with 0.025 ml aliquots ofserial, twofold dilutions of
rat serum.
Histology
The paw was fixed in 10 percent neutral buffered formalin, sectioned, and stained
with hematoxylin and eosin for histologic examination.
Cell Counts
Total leukocyte and platelet counts were determined by a coulter counter.
Neutrophil counts were calculated based on the percentage of neutrophils relative to
total white cell count present on a smear of peripheral blood.
RESULTS
A single dose of 100 itg E. coli LPS potently inhibited the local footpad swelling
that develops after an injection of M. butyricum. As shown in Table 1, the incre-
ment in footpad size 24 hours after mycobacteria injection was reduced from 3.92 ±
0.22 mm in the control rats to 1.90 i 0.22 mm in the rats treated with LPS three
hoursbefore adjuvant (p < .0005). LPS 24hoursbefore adjuvant alsohad a marked
effect in reducing footpad swelling (p < .0005), but minimal benefit was seen when
LPS was given 72 hoursbefore adjuvant. The beneficialeffect ofLPS was abrogated
ifLPS tolerance was induced by a schedule ofeight injections over an 11-day period,
TABLE I
Effect of LPS on Soft Tissue Swelling 24 Hours After Adjuvant Injectioni Locally
Multiple-Dose
Controls Single-Dose LPS LPS
Time of last LPS injection
relative to adjuvant - -3 hours -24 hours -72 hours -3 hours
Footpad swelling
(mm) (mean SE) 3.92 ± .22 1.90 .22 1.73 i .31 3.34 .36 3.82 t .23
Number of animals 24 8 7 6 8
p value relative to control <.0005 <.0005
Multiple-dose animals received 10 14g, 50 /g, and six 100 ,g doses of LPS over an I1-day period up to
and including the day adjuvant was given.
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even if the last dose of LPS was three hours before the adjuvant (Table 1). These
animals were tolerant since, with this schedule of injections, they failed to develop
the lethargy and diarrhea normally seen after 100 jig E. coli LPS.
The anti-inflammatory effects of LPS were not paralleled by either depletion of
total hemolytic complement or by neutropenia; 24 hours after 100 lOg of LPS, no
change could be detected in hemolytic complement titers and neutrophil counts rose
from 2,755 , 1,685/mm3 to 11,804 , 5,436/mm3 (n = 3). Platelet counts 24
hours after endotoxin did diminish from 726,000 + 38,000/mm3 to 254,000 +
19,000/mm3 (n = 3).
The effect of LPS on the local footpad swelling was transient. As shown in Fig. 1,
swelling increased daily in the adjuvant-injected footpad despite endotoxin pretreat-
ment. By day 6 after the adjuvant, the reduction in swelling in the adjuvant-injected
footpad was no longer significant. Furthermore, endotoxin pretreatment did not
consistently affect the arthritis that develops roughly two weeks after the adjuvant
injection. Using increment in footpad diameter in the uninjected hindfoot as an in-
dex of arthritis, we were unable to find a regimen of single or multiple LPS injec-
tions that consistently inhibited arthritis (Fig. 2).
In addition, LPS treatment did not consistently affect adjuvant arthritis once the
joint disease was established. LPS treatment for established arthritis was greatly
limited by the inability of rats with adjuvant arthritis to tolerate endotoxin. 100 jig
E. coli LPS was fatal to more that 50 percent of rats with active adjuvant arthritis,
which parallels the increased lethality of LPS in animals with mycobacteria infec-
tions [29] or those that have received Bacille Calmette-Guerin vaccine [30]. As
shown in Fig. 3, 10 jig of LPS after single or multiple doses did not affect the ar-
thritis due to mycobacterial injection.
Histologically the adjuvant injection induces a sterile abscess with a predominant
polymorphonuclear cell infiltrate 24 hours after injection. The histologic ap-
pearance of footpads from control and LPS-treated rats did not differ significantly,
i.e., LPS did not appear to influence the degree of cellular infiltrate qualitatively.
THE INHIBITION OF SWELLING IN THE ADJUVANT INJECTED FOOT
IS TRANSIENT
8
-o Saline Treated Control
-0 100 ,ug LPS 3 hr Before Adjuvont
--a LPS Tolerant
FIG. 1. The inhibition of swell-
m 4 -. ing in the adjuvant-injected foot
°2~ b ...........is transient. Although the rats
t, .'(n = 9) receiving a single injec-
2? t ,@tion of LPS had markedly less
sa, 2 t &' swelling at theadjuvant injection C site initially, by day 6 differences
between the controls (n = 7),
LPS-tolerant rats (n
= 7), and
-fsingle-dose treated rats are no
0 2 4 6 8 14 16 18 20 28 longer significant. Values given
Day Post Adjuvant are mean + SEM.
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LPS FAILS TO INHIBIT ADJUVANT ARTHRITIS
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FIG. 2. LPS fails to inhibit
adjuvant arthritis. Rats
(n = 9) that received 100Ag
of LPS three hours before
adjuvant did not have any
reduction in the arthritis or
footpad swelling that affects
the uninjected opposite
hindfoot. For controls,
n = 7. Values represent
mean ; SEM.
DISCUSSION
These studies establish that LPS can markedly but transiently inhibit inflamma-
tion due to mycobacterial adjuvant. We are unaware of a previous study that
demonstrates that LPS is anti-inflammatory in rats. The effect of LPS could not be
demonstrated if LPS was given in multiple doses or if it was given 72 hours before
the adjuvant. LPS did not consistently inhibit the subsequent arthritis in any treat-
ment regimen.
In 1962 Wood and Pearson reported that lipopolysaccharide could inhibit adju-
vant arthritis [20]. The LPS could only be given in mineral oil, not saline, in order to
be effective. It was injected 15 to 40 days before the adjuvant and could be derived
from gram-positive or gram-negative bacteria. Many factors make the Wood and
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FIG. 3. LPS fails to reduce
inflammation onceadjuvant
arthritis is established. Two
groups of eight rats were
treated either with LPS or
saline. The two groups were
initially comparable in terms
of severity of joint disease.
Neither single nor multiple
doses of LPS reduced the
progressive swelling in the
uninjected footpad. Values
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Pearson study not comparable to the present one, including the definition of
lipopolysaccharide, which most authorities now reserve for use in reference to gram-
negative bacteria. Transfer studies have clearly established adjuvant arthritis as an
immunologic disease [16]. Although LPS is normally considered an adjuvant itself,
LPS administration during certain times can also inhibit an immune response [13]. It
is possible that the effects that these investigators observed relate to immunologic ef-
fects of LPS. Our observations pertain more to LPS effects on acute inflammation
in which neutrophils rather than mononuclear cells appear to be primarily involved.
Our study demonstrates that the acute inflammation induced by M. butyricum can
be markedly diminished without affecting the subsequent immunologic inflamma-
tion.
Our own studies should be compared with the work of several investigators who
have studied the effect of endotoxin on active bacterial infection or the effect of en-
dotoxin on the leukocytic response to bacteria or bacterial products [32-36].
Depending on its dose and time of administration, LPS is capable of inhibiting the
migration of PMN in response to an intradermal or intraperitoneal inoculum of
bacteria and it can also enhance the lethality of such an infection [32-36]. Ofspecial
relevance to our own study is the observation of Delaunay and Pages that 1 mg of
endotoxin given systemically to guinea pigs inhibited the diapedesis of leukocytes
normally seen locally after the intradermal injection of acid-fast bacilli [32].
However, our study differs significantly from that reported by these investigators.
In addition to studying a different species with a lower dose of endotoxin, our own
histologic examination failed to show that the reduction in swelling could be at-
tributed to reduced polymorphonuclear leukocyte extravasation. No prior study has
evaluated the effect of endotoxin tolerance on this anti-inflammatory effect of LPS
or evaluated the relationship between inhibition of the initial footpad swelling with
the subsequent arthritis.
The possible relationship between endotoxin, adjuvant arthritis, and Reiter's syn-
drome was an added impetus for the present studies [37]. Reiter's syndrome is a reac-
tive arthropathy that may be preceded by a gram-negative dysentery [38] which in
turn can result in endotoxemia [39]. Reiter's syndrome is a multisystem disease that
includes eye, bowel, genitourinary, and cutaneous manifestations in addition to a
characteristic arthropathy. Rats with adjuvant arthritis may developjoint, eye, skin,
bowel, and genitourinary disease that histologically, clinically, and radiographically
resembles Reiter's syndrome [19]. Although LPS is anti-inflammatory, its failure in
rats to inhibit the arthritis of adjuvant disease is compatible with the observation in
man that Reiter's syndrome may begin subsequent to endotoxemia.
Having previously observed that endotoxin tolerance prevents endotoxin-induced
ocular vascular permeability [5] and reasoning that endotoxin and mycobacteria
(i.e., peptidoglycan) might induce swelling by a similar mechanism, we predicted
that endotoxin tolerance would inhibit mycobacterial inflammation more than a
single dose of endotoxin. To our surprise LPS tolerance abrogated the anti-
inflammatory effects of endotoxin. This, however, should be interpreted with cau-
tion. LPS tolerance can broadly be divided into an early form that appears to be a
pharmacologic tachyphylaxis and a later form due to the production ofneutralizing
antibodies [25]. The 11-day tolerance regimen used in these studies may have al-
lowed production ofantibodies such that the effective dose of LPS was less than 100
tig. The diminished reduction in footpad swelling in LPS-tolerant rats might merely
be a dose-dependent effect. Our studies cannot rule out this possibility but in ex-
298ENDOTOXIN AND ADJUVANT ARTHRITIS 299
amining the effect of LPS on reversed passive Arthus reactions in rabbit skin, we
have also noted that LPS tolerance diminishes the anti-inflammatory effects of LPS,
even when the tolerance was established with a regimen designed to minimize the
development of neutralizing antibodies [Rosenbaum JT, Howes EL, Goldstein IM:
Endotoxin tolerance diminishes the anti-inflammatory effects of endotoxin. Fed
Proc 41:558, 1982 (abstract)]. Intriguingly, Verghese and Snyderman have observed
that C3H/HeJ mice, which are genetically "tolerant" to toxic effects of LPS, also
are refractory to anti-inflammatory effects of LPS [12]. Other investigators have
found that LPS-tolerant rabbits are not protected from fever induced by synthetic
peptidoglycan [21].
These studies do not establish the mechanism of this LPS-mediated anti-
inflammatory effect. Neutropenia and complement depletion seem unlikely
possibilities. Hypotension or intercurrent illness are also unlikely since 24 hours
after this dose of LPS, the rats behave normally. In the rabbit, we have established
that LPS given in vivo inhibits the response of neutrophils to complement-derived
chemotactic stimuli [14]. However, the neutrophil exudation evident even in the
LPS-treated rats suggests that this mechanism is not the major explanation for the
results reported here. Other possible mechanisms include a stress-induced release of
adrenal steroids and/or catecholamines [40] or a stimulation of prostaglandin pro-
duction [41]. Given in large doses exogenously, prostaglandin E can inhibit inflam-
matory changes such as vascular permeability [42]. By inducing inflammation, LPS
might induce a tachyphylaxis to some of the mediators released by this inflamma-
tion. It is hoped that further studies can clarify the mechanism by which LPS can be
both inflammatory and anti-inflammatory as well.
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